Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate (ADC) designed to target HER2 mutations. We reported a case study demonstrating a favorable response to DS-8201 in a patient with HER2 mutation-positive non-small cell lung cancer (NSCLC) who exhibited resistance to initial immunotherapy...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1469438/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533236420804608 |
|---|---|
| author | Lu Wang Shidi Wen Wenjia Zhu Zhiyang Zhang Yuejuan Cheng |
| author_facet | Lu Wang Shidi Wen Wenjia Zhu Zhiyang Zhang Yuejuan Cheng |
| author_sort | Lu Wang |
| collection | DOAJ |
| description | Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate (ADC) designed to target HER2 mutations. We reported a case study demonstrating a favorable response to DS-8201 in a patient with HER2 mutation-positive non-small cell lung cancer (NSCLC) who exhibited resistance to initial immunotherapy, along with delayed immune-related events of hypoadrenocorticism occurring five months after discontinuation of immune checkpoint inhibitors. After reviewing the relevant literature, we discussed the mechanism of ADC agents underlying their anti-tumor activity and the potential impact of DS-8201 on the tumor microenvironment. This case highlights the efficacy of DS-8201 in NSCLC, particularly in individuals who have failed first-line immunotherapy, and provide valuable insights for clinicians exploring innovative strategies for the management of patients with lung cancer. |
| format | Article |
| id | doaj-art-6459ff6474eb40ee8848c485483758f7 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-6459ff6474eb40ee8848c485483758f72025-01-17T05:10:46ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14694381469438Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature reviewLu Wang0Shidi Wen1Wenjia Zhu2Zhiyang Zhang3Yuejuan Cheng4Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate (ADC) designed to target HER2 mutations. We reported a case study demonstrating a favorable response to DS-8201 in a patient with HER2 mutation-positive non-small cell lung cancer (NSCLC) who exhibited resistance to initial immunotherapy, along with delayed immune-related events of hypoadrenocorticism occurring five months after discontinuation of immune checkpoint inhibitors. After reviewing the relevant literature, we discussed the mechanism of ADC agents underlying their anti-tumor activity and the potential impact of DS-8201 on the tumor microenvironment. This case highlights the efficacy of DS-8201 in NSCLC, particularly in individuals who have failed first-line immunotherapy, and provide valuable insights for clinicians exploring innovative strategies for the management of patients with lung cancer.https://www.frontiersin.org/articles/10.3389/fonc.2024.1469438/fullantibody-drug conjugatetrastuzumab deruxtecanimmune-related adverse eventslung cancercase report |
| spellingShingle | Lu Wang Shidi Wen Wenjia Zhu Zhiyang Zhang Yuejuan Cheng Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review Frontiers in Oncology antibody-drug conjugate trastuzumab deruxtecan immune-related adverse events lung cancer case report |
| title | Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review |
| title_full | Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review |
| title_fullStr | Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review |
| title_full_unstemmed | Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review |
| title_short | Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review |
| title_sort | response to trastuzumab deruxtecan and delayed immune related events in a patient with metastatic her2 positive nsclc a case report and literature review |
| topic | antibody-drug conjugate trastuzumab deruxtecan immune-related adverse events lung cancer case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1469438/full |
| work_keys_str_mv | AT luwang responsetotrastuzumabderuxtecananddelayedimmunerelatedeventsinapatientwithmetastaticher2positivensclcacasereportandliteraturereview AT shidiwen responsetotrastuzumabderuxtecananddelayedimmunerelatedeventsinapatientwithmetastaticher2positivensclcacasereportandliteraturereview AT wenjiazhu responsetotrastuzumabderuxtecananddelayedimmunerelatedeventsinapatientwithmetastaticher2positivensclcacasereportandliteraturereview AT zhiyangzhang responsetotrastuzumabderuxtecananddelayedimmunerelatedeventsinapatientwithmetastaticher2positivensclcacasereportandliteraturereview AT yuejuancheng responsetotrastuzumabderuxtecananddelayedimmunerelatedeventsinapatientwithmetastaticher2positivensclcacasereportandliteraturereview |